Metabolische Effekte und allgemeine Nebenwirkungen bei Endometriose-behandlung mit einem LHRH-Agonisten

U Cirkel, Karl-Werner Schweppe, K W Schweppe, H Ochs, Hauke Schneider, H P Schneider
Geburtshilfe und Frauenheilkunde · 1987 · vol. 47(03) , pp. 154–157 · doi:10.1055/s-2008-1035798 · PMID:3108065 · W1972977688
article OA: closed CC0 ⤵ 8 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-07 ⓘ

Buserelin, an LHRH agonist, effectively treated endometriosis by suppressing ovarian function for six months without causing adverse metabolic or kidney/liver function changes.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by claude@2026-06, 2026-06-07 ⓘ

Between 1983 and 1986, the study enrolled 40 patients with external genital endometriosis and treated them with the LHRH agonist buserelin to achieve ovarian suppression for 6 months at 900–1,800 µg/day. Liver and kidney function and lipid metabolism were assessed prior to treatment and at regular intervals during therapy, alongside gynecological findings, and no deviations from normal ranges were reported. The general side effects observed were generally attributed to buserelin-induced relative estrogen deficiency, and treatment efficacy was demonstrated by control pelviscopy. This paper is centrally about endometriosis — it evaluates metabolic effects and general side effects of buserelin during medical treatment of external genital endometriosis.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

Between 1983 and 1986 40 patients were treated for external genital endometriosis with the LHRH agonist buserelin. Ovarian suppression was achieved for a period of six months with a dose of 900 to 1,800 mcg per day. In addition to gynecological findings, liver and kidney function and lipid metabolism were checked prior to treatment and at regular intervals during treatment. No deviations from normal ranges were found. The general side effects observed during treatment were as a rule attributable to the buserelin-induced relative estrogen deficiency. The efficacy of the medication in the treatment of endometriosis was demonstrated by control pelviscopy. Since no undesirable metabolic side effects have so far been observed with buserelin, it may be considered an effective new alternative treatment for endometriosis.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Buserelin Endometriosis Energy Metabolism Genital Neoplasms, Female Adult Buserelin Buserelin Endometriosis Energy Metabolism Female Genital Neoplasms, Female Humans

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

Cited by (8)

Source provenance

europepmc
last seen: 2026-06-21T06:12:49.409960+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:09:30.565292+00:00
License: CC0 · commercial use OK